Romanian Society of Pharmaceutical Sciences

« Back to Farmacia Journal 2/2014

PROTEASOME INHIBITION: RECENT ADVANCES IN ANTITUMORAL THERAPY

ELENA CAMELIA STĂNCIULESCU1, CĂTĂLINA GABRIELA PISOSCHI1*, GABRIELA RĂU1, ANA-MARINA ANDREI1, MONICA BANIȚĂ2

University of Medicine and Pharmacy of Craiova, Romania
1.Faculty of Pharmacy
2.Faculty of Dentistry

Download Full Article PDF

The major pathway for degradation of intracellular proteins is the ubiquitin-proteasome pathway. There is increasing evidence revealing that the dysregulation of the ubiquitin-proteasome pathway are involved in pathogenesis of many diseases such as cancer and neurodegenerative disorders. Many studies are focused now on developing new drugs that target ubiquitin-proteasome pathway, based on the observation that proteasome inhibition induces apoptosis in many tumor cells. This review exposes recent data concerning the use of proteasome inhibitors in cancer therapy.